Patient-centered Care for Genitourinary Cancers
Community oncologists are challenged to stay up to date with updated clinical practice guidelines on the personalization of treatments for genitourinary (GU) cancers, including prostate, urothelial, and renal cancers, combination/sequential therapies, emerging safety and efficacy data from ongoing studies of novel regimens, and strategies to facilitate patient engagement in order to improve patient outcomes. Clinicians need tools and resources to help educate their patients and empower them to participate in their care and make educated treatment choices. Advanced-stage GU cancers consists of a spectrum of disease that requires an integrated multidisciplinary approach supported by a uro-oncologic team. Therefore, it is critical to educate these clinicians on their roles within the multidisciplinary cancer care team and on the importance of effective communication with other members of the team to maximize patient outcomes.
This activity has been designed to meet the educational needs of healthcare professionals involved in the diagnosis, treatment, or management of patients, including:
- Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
- Oncology nurses, advanced practice nurse (APNs), and nurse practitioners (NPs); primary point persons for patient management and education
- Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
- Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)
Upon completion of this activity, participants will be better able to do the following:
- Incorporate treatment pathways and quality measures to ensure patients receive guideline-consistent care
- Evaluate the sequential and combination administration of chemotherapy and targeted agents to optimize survival in patients with genitourinary cancers
- Discuss current recommendations for diagnostic testing for genitourinary cancers to facilitate treatment selection
- Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of genitourinary cancers with attention to cost/benefit and toxicity considerations
- Evaluate communication strategies and resources to increase patient access and engagement
Mark Stein, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Mark Stein, MD
Grant/Research Support: Janssen Inc; Oncoceutics, Inc.
Non-faculty: Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The non-faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
|Non-faculty||Relationship Identified With:|
Gary I. Cohen, MD
Speakers’ Bureau: Genzyme Corporation; NantHealth
Shareholder: Celgene Corporation
|Alex Ganetsky, PharmD|
Honoraria/Advisory Board: Jazz Pharmaceuticals Inc.
Speakers’ Bureau: Amgen Inc; Incyte Corporation
This activity has been supported by an independent educational grant from Sanofi Genzyme.
Jointly provided by the Elsevier Office of Continuing Medical Education, the Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Rockpointe Oncology. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE CREDIT (NURSES)
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Elsevier Office of Continuing Medical Education, the Potomac Center for Medical Education, and Rockpointe Oncology. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Designated for 0.9 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
CE CREDIT (PHARMACISTS)
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.
The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 hour (0.125 CEUs) of continuing education credit (UAN: 0418-9999-18-204-H04-P).
This is an application-based activity.
CME/CNE INQUIRIES/SPECIAL NEEDS
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, the Potomac Center for Medical Education, Postgraduate Institute for Medicine, Rockpointe Oncology, and Genzyme Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.25 ACPE
- 1.25 AMA PRA Category 1 Credit(s)™
- 1.20 Nursing Contact Hours
- 1.25 Non-physician